Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Hold" from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Hold" from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $9.29.

Several brokerages have commented on NMRA. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, April 10th. Guggenheim downgraded Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, March 7th. Stifel Nicolaus downgraded Neumora Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Bank of America reaffirmed an "underperform" rating and issued a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Finally, William Blair cut shares of Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NMRA. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Neumora Therapeutics during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. acquired a new position in Neumora Therapeutics during the 4th quarter valued at approximately $64,000. Quantbot Technologies LP acquired a new position in Neumora Therapeutics during the 4th quarter valued at approximately $92,000. PEAK6 LLC acquired a new position in Neumora Therapeutics during the 4th quarter valued at approximately $117,000. Finally, EntryPoint Capital LLC acquired a new position in Neumora Therapeutics during the 4th quarter valued at approximately $135,000. Institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded up $0.05 during mid-day trading on Wednesday, hitting $0.72. The company's stock had a trading volume of 197,689 shares, compared to its average volume of 1,492,630. The company has a 50 day moving average of $0.92 and a 200-day moving average of $4.64. The stock has a market cap of $115.97 million, a PE ratio of -0.38 and a beta of 2.96. Neumora Therapeutics has a one year low of $0.62 and a one year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, equities research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.